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INTRODUCTION
Innumerous advances in biotechnology over the past few 
decades, in particular in the area of recombinant DNA 
technology (1), have produced a number of protein- and 
peptide-based (bio)pharmaceutical products approved for 
the treatment of a large number of human affl ictions. As 
scientifi c areas such as genomics and proteomics continu-
ously mature in development, additional macromolecules 
with potential therapeutic applications are likely to be dis-
covered (2), refl ecting the growing importance of biotech-
nology-derived (macro)molecules as therapeutic candidates 
(3,4). Biosynthetic advances, mainly based on recombinant 
DNA technology, are enabling the availability of increas-
ingly complex protein molecules including those with mul-
tiple specifi c carbohydrate moieties (4–7). In the same 
way, solid-phase synthesis is now capable of producing 
high-purity peptides and macropeptides up to ca. 40 amino 
acid moieties (8). The ability to engineer specifi c func-
tional properties of protein macromolecules, such as higher 
potency, further increases the likelihood of commercial 
success by reducing both dose requirements and the amount 
of active (bio)pharmaceutical ingredient.
Notwithstanding the (bio)technological advances leading 
to the discovery of growing numbers of new protein and pep-
tide molecules, potential candidates for pharmacological 
applications, the challenges associated with both formulating 
and administering such types of molecules still remain high 
(9–11). An assessment of the commercially available protein- 
and peptide-based biopharmaceutical products shows that the 
major formulation strategy involves lyophilization, with 
delivery being effected via subcutaneous, intramuscular, or 
intravenous injection (12). Whereas the need to reconstitute a 
lyophilized pharmaceutical product prior to administration is 
essentially a convenience issue, the subsequent mode of 
delivery strongly limits product potential in the market 
because patients do not readily accept injections, especially 
in the treatment of chronic diseases. Only a few ready-to-use 
pharmaceutical formulations of proteins and peptides in solu-
tion are available in the market and minimize to some extent 
the inconvenience of dose preparation, but however do not 
address the invasive nature of administration.
Many carriers of protein and peptide moieties, such as 
nanoparticles, liposomes, micelles, nanoemulsions and micro-
emulsions have been studied as delivery systems to obtain 
better therapeutical effi cacy (13–16). A complete review on 
this subject was provided by Moutinho and colleagues (1).
Since it is generally recognized that injection-based 
delivery methods for biopharmaceuticals are a major 
impediment to the commercial success of therapeutic pro-
teins and peptides, scientifi c research in both academia and 
industry continues to focus on ways to overcome this prob-
lem. Indeed, all possible routes of administration have been 
under scrutiny for the systemic delivery of protein- and 
peptide-based biopharmaceuticals by non-invasive routes, 
including nasal, buccal/sublingual, oral, trans-dermal, pul-
monary, ocular, vaginal, and rectal. The large surface area 
associated with most of the aforementioned routes makes 
them attractive targets for drug delivery (Table 1).
 Although biopharmaceutical administration by these routes 
(Table 1) is considered a more logical and achievable option 
for non-invasive local treatments, systemic delivery of protein 
and peptide molecules is signifi cantly more challenging. 
However, scientifi c studies designed and conducted to dem-
onstrate the feasibility of systemic delivery of such biophar-
maceutical molecules are often carried out in animal models, 
leaving highly uncertain translation of the fi ndings to human 
subjects. Some of the scientifi c research has evolved to evalu-
ation in human patients, but many of the reported successes 
fail to address how the technology will be transformed into a 
commercial product. The only remarkable exceptions have 
been the successful commercialization of nasal formulations 
for systemic delivery of a limited number of therapeutic pep-
tides, and the quite regulatory approvals of both pulmonary 
and buccal delivery systems for systemic delivery of insulin. 
Furthermore, an oral formulation of a small peptide analog 
(cyclosporin) has been commercialized, but this molecule is 
not entirely representative of typical proteins and peptides 
since it contains unnatural amino acid moieties.
Currently, there are more than 885 protein-based phar-
maceuticals in clinical studies, with an extensive market 
potential for protein-based therapies. The impact of 
biotechnology-derived products on the pharmaceutical 
2 Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition, Volume 1
Proteins and P
eptides:
 N
on-In
vasive Delivery
 industry can be demonstrated by the fact that ca. 30–40% 
of new drug approvals are in the “biological category”, 
including proteins and peptides (20).
A demand for conversion of therapeutically active pro-
teins and peptides into widely used medicines is increa-
sing, consequently intensifying demands for improved 
 formulations. Such new formulations need to more ade-
quately address the pharmacological and therapeutic require-
ments for each particular protein and/or peptide molecule. 
This not only means to search for alternative routes to a par-
enteral administration but, crucially, through the develop-
ment of new formulations to increase the range of therapeutic 
proteins that can be used clinically.
This chapter examines the current status of non-invasive 
delivery of protein and peptide biopharmaceuticals, with par-
ticular emphasis on technologies that appear to offer a viable 
solution to overcoming the challenges associated with deliv-
ering this class of macromolecules. Factors pertinent to the 
technological development and the issues infl uencing poten-
tial realization of commercial products based on a given tech-
nology are also considered and scattered throughout the text.
NON-INVASIVE (MUCOSAL-BASED) DELIVERY
Lungs, skin and GIT are all in direct contact with the environ-
ment. These organs are likely to be a fi rst port of entry for 
nanomaterials encasing proteins and/or peptides into the 
body (21). The physicochemical properties of most peptide 
and/or protein moieties, such as their molecular size, hydro-
philicity, susceptibility to proteolytic degradation and lack of 
absorption, exclude them from being delivered via other 
potential routes of administration. The notion of non-invasive 
protein delivery took an extraordinary impulsion with the 
approval and marketing of Exubera®, a pulmonary insulin 
formulation that was available from September 2006 to 
 October 2007 in the United States of America (USA). Cur-
rently, there are very few marketed non-parenteral protein 
formulations, including nasal calcitonin spray (Fortical®) and 
a buccal formulation of insulin (Oralyn®), with a few peptide 
formulations for either oral or nasal administration (20).
In essence, there are extensive similarities in the barriers 
presented to non-invasive protein and peptide delivery via 
oral, pulmonary or intranasal routes, although, depending on 
the route, the intensities of these obstructions (enzymatic 
degradation, mucous layer, ciliated cell membrane, as well 
as the expression of surface receptors on epithelial cells) are 
dissimilar. The fi rst physiological barrier, a mucociliary 
clearance, has evolved to effectively remove deposited 
material, and it is frequently controlled by the use of muco-
adhesive materials such as chitosan, polyacrylic acid deriva-
tives or thiolated polymers. These (bio)materials bind 
non-specifi cally to the mucus (through formation of ionic 
bonds, hydrogen bonds, van der Waals and/or hydrophobic 
interactions), and in this way extend the residence time of 
the delivery system (20). Second-generation approaches 
focus on bioadhesion, highly specifi c and direct interactions 
with receptors or receptor-like structures on the apical mem-
brane of epithelial cells. These are based on plant lectins, 
which bind specifi cally to the sugar moieties of the glycoca-
lyx expressed on the intestinal epithelial cells, which are 
generally resistant to digestion within the GIT (22).
Bioadhesion phenomena presents new perspectives to 
trans-mucosal delivery of peptides and proteins, as: (i) the 
attachment to cell surfaces is independent of mucus turnover; 
(ii) there is a potential for achieving site targeting, and also 
(iii) there is a possibility of triggering endocytotic uptake and 
trans-cytosis by epithelial cells. This approach is being par-
ticularly exploited in the design of vaccine  formulations (22).
Table 1 Available options for the non-invasive delivery of both protein and peptide molecules
Administration route Estimated surface areaa (m2)
Level of enzymatic activity 
(17)
Trans-dermal 1–2 +
Pulmonary 100 +
Buccal 0.01 ++
Nasal 0.015 ++
Vaginal 0.036 +
Ocular (Area corresponds to human conjunctiva. Pharmaceuticals 
delivered by this route are also absorbed through inferior nasal 
and gastrointestinal mucosa) (18)
0.0018 n.a.
Rectal 0.02–0.04 +++
Oral (19)
+++++++
 Gastrointestinal tract (GIT) 200
 Stomach 0.1–0.2
 Small intestine
  As a whole 100
  Taking intestinal microvilli into account 4500
 Large intestine 0.5–1.0
aFor source details, please refer to references cited throughout the text.
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The fundamental step for transport to occur through 
the mucosal surface is to cross the epithelial cell lining. For 
large peptide and protein macromolecules, the transport 
can occur exploiting either paracellular (tight junctions) or 
trans-cellular routes. The mucosal epithelial cells are 
 connected by tight junctions, with paracellular spaces in the 
order of 10 and 30–50 Å. This suggests that a “particle” with 
a radius greater than 15 Å (approximately 3.5 kDa) cannot be 
transported via this route. Accordingly, the delivery of large 
peptides and proteins across mucosal epithelia using the 
paracellular pathway is strictly limited. However, incorpora-
tion of the so-called permeation enhancers into protein-based 
formulations has been shown to increase the permeability of 
the mucosal epithelium. Permeability enhancement has been 
reported following utilization of excipients with diverse char-
acteristics, which perform via different mechanisms, includ-
ing rising membrane fl uidity (e.g. surfactants), decreasing 
mucus viscosity (mucolytic agents), and disrupting tight 
junctions (chitosan, calcium chelators such as EDTA) (23).
Formulations for delivery of peptide and protein biophar-
maceuticals across the mucosal surfaces are often based on 
designing nano-sized carriers (1). These are typically poly-
meric particles, complexes or liposomes, normally sur-
face-modifi ed/decorated by mucoadhesive moieties and 
permeability enhancing materials (24). The use of these 
systems eliminates the need for chemical conjugation and 
also protects incorporated proteins and peptides from the 
action of intestinal proteolytic enzymes. Stabilization of the 
protein and/or peptide moieties can also be correlated with 
a change in the thermodynamical conditions of the environ-
ment surrounding each particle, since the movements of 
solvent (water) molecules in their microneighbourhood are 
seriously restricted by the effect of encapsulation, which is 
in agreement with postulated stabilization mechanisms for 
protein residues by Ragoonanan and Aksan (25).
OVERVIEW ON GENERAL BARRIERS 
TO NON-INVASIVE DELIVERY
Although each potential site for non-invasive administration 
of biopharmaceutical molecules such as peptides and proteins 
has its own unique features, some general barriers to delivery 
do exist. Such barriers can be broadly categorized as physico-
chemical (structural), enzymatic, and cellular (physical). The 
physicochemical barrier relates specifi cally to the complex 
structural properties specifi c to proteins and peptides. The 
enzymatic barrier deals with the susceptibility to proteolytic 
enzymes associated with a given route of delivery, and the 
cellular barrier refers to the epithelial membrane that must be 
crossed by the biomolecules for absorption into systemic cir-
culation. All these types of barriers will be detailed below.
Physicochemical Barrier
The unique physicochemical properties of protein and pep-
tide (macro)molecules impart a level of structural complex-
ity not usually encountered with traditional, low-molecular 
weight pharmaceuticals. To retain the therapeutical effect, 
the integrity of the primary (linear sequence domain), sec-
ondary (local folding domains), tertiary (global folding 
domain) and quaternary (assembly of multiple subunits, in 
the case of multimeric proteins) structural elements specifi c 
to a given protein or peptide  molecule must be properly 
maintained. Any disruption of these properties can lead to 
diminished activity or impart serious toxicological, immu-
nological, or pharmacological consequences (10,11,26). 
Therefore, much of the time and effort invested in develop-
ing protein and peptide (bio)pharmaceuticals relates to 
understanding which factors will negatively impact their 
native structure, and devising means to control or eliminate 
potentially deleterious effects.
Protein and peptide molecules can be chemically or phys-
ically denaturated by a variety of mechanisms (27). Specifi c 
individual aminoacids, or sequences of aminoacids, are 
subject to chemical transformations such as deamidation, 
oxidation, covalent cross-linking, disulfi de scrambling, and 
fragmentation, resulting from exposure to extremes of pH 
and temperature, hydrophobic air interfaces, metal ions, or 
chemical agents. Physical denaturation pathways involve 
disruption of higher-order structural domains (e.g., folding 
- in the case of monomeric proteins) and assembly (in the 
case of multimeric proteins)) induced by mechanical (agita-
tion or shear) stress, air-liquid (hydrophobic-hydrophilic) 
interfaces, solvents, pH and/or temperature extremes. 
Aggregation, precipitation, and surface adsorption, are 
undesirable consequences of physical denaturation of pro-
teins. The factors involved in manufacturing operations, 
distribution, storage, and handling, of injection-based pro-
tein and peptide therapeutical formulations, in general, can 
all potentially expose them to conditions that may result in 
disruption of the native structure of said proteins and pep-
tides. Each of these aspects must be carefully examined 
during product development, to ensure that the structural 
integrity of the molecules is maintained. Extensive studies 
are also being performed to demonstrate that the fi nal bio-
pharmaceutical products have suffi cient stability over their 
shelf-life (typically 1.5–2 years, for commercial products), 
because time-dependent degradation of the protein or pep-
tide molecules can negatively infl uence potency, pharma-
cology, immunogenicity, or toxicology profi les (10,11,26).
The general requirements related to maintenance of both 
structural integrity and stability will apply to non-invasive 
delivery systems for proteins and peptides. Formulation strat-
egies, manufacturing processes, and delivery mechanisms, 
associated with non-invasive systems can include exposure to 
pH extremes, organic solvents, higher temperature, high 
shear, severe agitation, air-liquid interfaces, formulation addi-
tives (e.g., permeation enhancers) or other unfavorable condi-
tions, all capable of causing chemical or physical denaturation. 
Many of these situations are not typically encountered (or are 
completely avoided) with injection-based (invasive) systems 
for proteins and peptides. Since structural complexity and 
inherent fragility are common traits of protein and peptide 
molecules, there is no simple way to overcome the physico-
chemical barrier to non-invasive delivery. Devising appropri-
ate formulation and processing strategies that both minimize 
or eliminate any impact to the (fragile) structural properties of 
said biomolecules is the only way to manage this problem. If 
a device is required to deliver a formulation, then additional 
testing and controls are needed to ensure full integrity of the 
active protein or peptide molecules.
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barrier to the effective absorption of both protein and pep-
tide moieties into systemic circulation, and the large 
molecular weights and relatively hydrophilic nature of 
these macromolecules does not favor effective permeation. 
The mechanism of protein and peptide absorption has been 
extensively studied by many researchers but, however, the 
exact details about such process(es) remains poorly under-
stood. A general, but somewhat simplifi ed, representation 
of the cellular barrier (Fig. 1), is often used to describe 
pathways for absorption. Potential mechanisms of trans-
port across cells include: passive paracellular, passive tran-
scellular, facilitated transcellular, active carrier-mediated, 
and trans-cytosis. Although the cellular barrier for each 
non-invasive delivery route is more complex than what is 
depicted in Fig. 1, paracellular and trans-cellular transports 
are typically proposed as likely mechanisms for absorption 
of protein and peptide molecules.
Much is known about the specifi c anatomical, histologi-
cal, and physiological features of each absorption site, and 
the design of effective delivery systems must take these 
aspects into consideration so that maximum absorptive 
potential can be achieved. In most cases, the epithelium is 
composed of multiple layers of cells, each having specifi c 
structural properties (viz. dimensional characteristics, ker-
atin, or cilia). Adding to this complexity is the local physi-
ology connected with the target route. Cellular secretions 
such as mucus, saliva, or other fl uids lining epithelial sur-
faces, together with the mechanical effects resulting from 
ciliary action, can add up to minimize residence times of 
protein and peptide therapeutical molecules at the site of 
absorption. Other clearance mechanisms may also be pres-
ent (e.g., macrophages in the lungs), that can effectively 
eliminate protein or peptide molecules prior to their absorp-
tion. Finally, each potential delivery route is part of a 
dynamic system subject to changes in cellular and molecu-
lar organization brought about by normal processes (e.g., 
menstrual cycle or aging process), or resulting from other 
factors such as allergies, infections, illness, disease, disor-
ders, and other lifestyle habits (e.g., smoking). A general 
strategy for overcoming the cellular barrier consists in 
incorporating permeation enhancers into formulations 
intended for non-invasive routes of administration (28,29). 
Table 2 lists some representative permeation enhancers 
screened for potential use in non-invasive delivery systems 
of proteins and peptides. Commonly accepted mechanisms 
of action of said permeation enhancers are also included in 
Table 2, which typically involve disruption of the cellular 
architecture and/or molecular interaction with the protein 
and peptide molecules to facilitate transport. Cell damage 
and non-specifi c absorption are key concerns associated 
with the use of permeation enhancers, together with the 
impact of these agents on the structural properties of pro-
tein and peptide biopharmaceuticals (30).
PHARMACOKINETIC AND PHARMACODYNAMIC 
CONSIDERATIONS
A threshold level of systemic drug concentration and an opti-
mal duration of exposure (pharmacokinetics, PK) following 
administration of a protein or peptide biopharmaceutical are 
Enzymatic Barrier
Protein and peptide moieties are accessible to enzymatic 
(proteolytic) action due to the susceptibility of specifi c 
amino acid sequences, and such proteolysis is an in vivo 
naturally occurring metabolic process. Degradation path-
ways generally involve hydrolysis of peptide bonds by a 
variety of exopeptidases and endopeptidases, and the spe-
cifi c proteolytic enzymes associated with non-invasive 
routes of administration have been identifi ed in some detail 
by several researchers (17,28). Enzymatic activity varies 
largely depending on the delivery route (Table 1). Since a 
signifi cant portion of the protein intake consumed by 
humans is assimilated by means of a highly evolved and 
effective digestive system, it is not surprising that the high-
est enzyme levels are associated with the oral route. The 
pulmonary and trans-dermal routes are considered to be 
relatively low in enzymatic activity, whereas the levels of 
enzymatic activity in all the other sites are intermediate. It 
is important to note that proteolytic enzymes are ubiqui-
tous and are present, for example, in the blood, liver, kid-
neys, and vascular endothelia. Thus, in addition to the site 
of absorption, protein and peptide molecules may experi-
ence the enzymatic barrier en-route to (e.g., hepatic fi rst-
pass metabolism following oral absorption) and in systemic 
circulation.
An obvious strategy to overcome the enzymatic barrier 
involves co-administration of inhibitors in formulations for 
non-invasive delivery systems. Some examples described 
in the scientifi c literature include (but are not limited to): 
aprotonin, boroleucine, puromycin, trypsin inhibitor, chy-
motrypsin inhibitor, ethylenediaminetetraacetic acid 
(EDTA), phosphinic acid analog, and bestatin (a potent 
inhibitor of some aminopeptidases) (17,29). Since multiple 
enzymes are implicated in degradation pathways, combi-
nations of inhibitors are typically required. Furthermore, 
use of these agents alone will not overcome the cellular 
barrier. Potential physiological and toxicological conse-
quences associated with the use of these agents must be 
considered when employing this strategy for the design of 
non-invasive delivery systems.
Structural modifi cations and formulation are two addi-
tional approaches proposed for overcoming the enzymatic 
barrier (28). Using recombinant DNA technology or syn-
thetic techniques, selective modifi cations to the protein or 
peptide sequence can be introduced, thus effectively reduc-
ing proteolytic susceptibility, but these changes must not 
have a signifi cant impact on the pharmacological proper-
ties of the biomolecule (e.g., reduced potency or altered 
selectivity). Moreover, modifi cations to address a specifi c 
enzymatic action will not eliminate vulnerability to others. 
The formulation approach essentially involves encapsula-
tion systems to protect the protein or peptide molecules 
from reactions with enzymes, and selected examples 
include emulsions, multiple emulsions, liposomes, 
nanoparticles, or enteric-coated capsules (1,28).
Cellular Barrier
The cellular architecture associated with each non-invasive 
route of administration represents a formidable physical 
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dosing regimens. In addition, the required exposure must be 
appropriately balanced against toxicological safety margins 
and control of any undesired side effects. Thus, both the phar-
macology and toxicology of a molecule determine the thera-
peutical window, which is the ratio between the maximally 
both necessary to produce the desired therapeutical effect 
(pharmacodynamics, PD). PK and PD parameters must be 
fully understood in both animal models and human subjects 
to demonstrate the therapeutical utility of the molecules and 
therefore enable selection of both dose levels and suitable 
Mucosal/apical
side
A B C D E F
Serosal/basolateral
side
Aqueous
boundary layer
and mucus layer
Basement membrane
Tight
junction
Blood vessel
Figure 1 Schematic illustration of potential mechanisms of transport across the cellular barrier. (A) passive transcellular, (B) via trans-
cytotic vesicles; (C) active carrier-mediated, (D) facilitated transcellular, (E) passive paracellular via tight junctions, and (F) trans-cytosis. 
Table 2 Types of permeation enhancers used in non-invasive delivery systems for protein and peptide molecules (28,29)
Class Examples Postulated mechanism of action
Bile salts Sodium deoxycholate -Formation of reverse micelles, solubilization of proteins/peptides 
-Removal of epithelial cells and formation of transient pores 
-Inhibition of proteolytic activity 
-Reduction of mucus viscosity
Sodium glycocholate
Sodium taurocholate
Dihydrofusidates (DHF) Sodium tauro-DHF -Formation of micelles 
-Inhibition of proteolytic activity 
-Perturbation of membrane layers
Sodium glyco-DHF
Sodium phospho-DHF
Complexing and chelating agents Cyclodextrins -Formation of inclusion complexes 
-Increase in stability 
-Increase of paracellular transport by (i) removing calcium ions, and (ii) 
widening of tight junctions
EDTA
Salicylates
Citric acid
Surfactants Sodium lauryl sulfate -Solubilization of proteins/peptides 
-Perturbation of membrane layers 
-Extraction of membrane proteins and lipids
Polyoxyethylene 
oxide-9 ethers
Fatty acids and derivatives Sodium caprylate
-Increase membrane fl uidity by (i) creating disorder in phospholipid 
domain of the membrane, and (ii) facilitating the leaching of proteins 
from the membrane
Sodium caprate
Sodium laurate
Oleic acid
Monoolein
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the patient population, and whether treatment is chronic 
vs. acute. Thus, in addition to the cost of manufacturing, the 
mere feasibility of producing such large-scale quantities 
must be thoroughly evaluated. If the technology requires 
the use of delivery agents, enzyme inhibitors and/or absorp-
tion enhancers as part of the formulation, the cost of pro-
duction associated with these molecular entities must also 
be considered. In the same way, a technology requiring a 
specifi c device to administer a formulation will result in 
additional manufacturing costs.
With the exception of a few approved products for the 
nasal administration of peptides, and the very regulatory 
approvals of delivery systems for both pulmonary and 
buccal delivery of insulin, there is relatively little prece-
dence with the worldwide regulatory approval process for 
non-invasive delivery systems incorporating protein or 
peptide biopharmaceuticals. It is reasonable to expect that 
delivery systems utilizing chemical agents to affect 
absorption will require rather comprehensive and lengthy 
toxicological studies to demonstrate acceptable safety 
profi les in human subjects, particularly in chronic use 
situations. Specifi c details concerning requirements for 
chemistry, manufacturing, and control data are also lack-
ing at the present time. It can also be anticipated that data 
covering a broad range of experimental factors, including 
information acquired under extreme stress (e.g., tempera-
ture, relative humidity, and/or mechanical agitation) con-
ditions, will be necessary to demonstrate the overall 
performance and reliability of the delivery system, espe-
cially if a device is involved. Data demonstrating struc-
tural integrity of the protein or peptide molecule in 
the formulation throughout shelf-life and during the in-
use period, will likewise be required. Collection of all the 
necessary data to support a regulatory submission involv-
ing a non-invasive delivery system will ultimately add 
both time and cost to the overall development process.
Assuming that a particular non-invasive protein or pep-
tide delivery system can be developed and can ultimately 
gain regulatory approval, there are additional factors 
related to patient and/or healthcare professionals that could 
ultimately infl uence whether the technology is successful 
in the commercial market. Simplicity of design is a key 
attribute, since physicians or patients will not readily 
accept highly complex delivery systems that are cumber-
some and diffi cult to use particularly when self-administra-
tion is involved in the treatment regimen. There are also 
inherent disadvantages associated with some of the routes 
available for non-invasive delivery. For example, patient 
acceptance of ocular, rectal, or vaginal administration is 
not anticipated to be very high. Although exploratory stud-
ies evaluating the feasibility of ocular, rectal, and vaginal 
delivery have been reported by several researchers (18,33–
35), numerous complicating factors shed some doubt on 
the commercial viability of delivery systems intended for 
administration by these routes, except perhaps for local 
treatment. There are obvious concerns over the potential 
impact on vision resulting from ocular delivery, particu-
larly in chronic treatment situations. Rectal administration 
faces signifi cant psychological barriers, hampering patient 
acceptance, and interruptions resulting from defecation can 
tolerated dose and the minimally effective dose, dictating the 
degree of PK control that needs to be achieved. Depending 
on the medical condition, either a bolus (rapid onset and 
elimination), basal (sustained level), or a pulsatile exposure 
profi le of the pharmaceutical agent in systemic circulation 
may be required. However, achieving a specifi c profi le is 
often diffi cult because many factors can infl uence the PK 
profi le following administration of a protein or peptide bio-
pharmaceutical, including (but not limited to): properties of 
the biomolecule, formulation conditions, route, and/or site of 
administration, and natural clearance mechanisms. Evidence 
also indicates that gender and race differences can further 
infl uence the pharmacological response to therapeutical 
agents (31,32). One additional complicating factor associated 
with non-invasive delivery is the limited availability of 
 validated in vitro and animal models that allow the accurate 
prediction of PK/PD responses in human subjects.
Normally, the strategies devised to modulate the PK pro-
fi le achieved with injection-based therapy of insulin may 
not produce the same pharmacological outcome in a non-
invasive delivery system. A formulation approach may not 
be directly transferable to a non-invasive delivery system 
because additives needed to effect absorption may be 
incompatible with an existing composition, or the specifi c 
requirements to reach the target site may require a totally 
different design. Moreover, use of an absorption enhancer 
to overcome the cellular barrier could also facilitate a very 
rapid transport of the active agent into systemic circulation, 
resulting in an undesirable burst effect. In the case of 
 insulin analogs, the designed molecular properties may not 
produce the same PK profi le when administered by a non-
invasive route due to environmental differences at the site 
and characteristics associated with absorption. The PK and 
PD considerations described above are applicable to all 
protein and peptide moieties with biopharmaceutical 
 applications, and therefore must be carefully evaluated to 
determine the suitability of a given non-invasive route 
of administration.
FACTORS INFLUENCING COMMERCIAL 
FEASIBILITY OF NON-INVASIVE DELIVERY 
METHODS
The availability of technologies that overcome the general 
barriers to non-invasive delivery of protein and peptide 
molecules and address the pharmacological needs associ-
ated with a particular therapy, will not necessarily guarantee 
commercial feasibility. Although advances in biotechnol-
ogy have enabled production of large amounts of highly 
purifi ed (recombinant or native) proteins and/or peptides 
for use as biopharmaceutical entities, there are additional 
constraints when considering non-invasive delivery sys-
tems. Typical values reported for bioavailabilities in most 
human proof-of-concept studies evaluating non-invasive 
protein or peptide delivery technologies range from 1% to 
10%, suggesting that tremendous increases in annual pro-
duction may be required to supply a commercial market 
compared to treatment using a conventional injection-based 
approach. The absolute amounts of protein/peptide moieties 
required will further depend on the target disease, size of 
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enzyme inhibitors in the formulations, or specifi c chemi-
cal modifi cations of the biomolecules to increase lipophi-
licity (37). As stated, a common problem encountered 
with conventional solutions or tablet dosage forms is the 
lack of retention at the absorption site due to continuous 
dilution by salivary fl ow. Therefore, immobilized bioad-
hesive delivery systems (tablets or patches) have been 
developed to extend the residence time at the site of 
absorption, thus allowing to achieve therapeutical drug 
levels. Bioadhesion is defi ned as the attachment of natural 
or synthetic biocompatible polymers to a biological sub-
strate, and examples of bioadhesive agents include (but 
are not limited to): hyaluronic acid, chitosan, cellulose 
derivatives, polyacrylates, gelatin, and agarose (37,38). 
Conventional solutions or tablet delivery systems rarely 
result in measurable absorption, with the bioavailabilities 
being typically much lower than ca. 10%. In general, bio-
adhesive systems tend to yield higher bioavailability. Gut-
niak and co-workers (42) evaluated a bioadhesive, 
biodegradable buccal tablet formulation of glucagon-like 
peptide amide in human subjects with Type-II diabetes. 
Although potentially therapeutic levels were demonstrated 
via such delivery system, the aforementioned authors con-
cluded that further development was required since an 
extended duration PK profi le would be necessary for opti-
mal therapy with this pharmaceutical peptide. The research 
work developed by Gutniak and co-workers (42) clearly 
demonstrates that simply achieving effective absorption 
of a therapeutic agent may not be suffi cient to ensure com-
mercial feasibility of a non-invasive delivery system. 
Departing from typical buccal/sublingual delivery system 
design strategies, Modi and co-workers (43) described a 
solution formulation containing insulin and absorption 
enhancers (Oralin™), administered as a fi ne mist into the 
oral cavity using a metered dose inhaler. The results 
of clinical studies evaluating this buccal delivery system 
in healthy subjects as well as in patients with Type-I or 
Type-II diabetes have been reported by several researchers 
(43,44). In healthy subjects and Type-I diabetes patients, 
the PK profi le obtained with OralinTM was similar to that 
observed for subcutaneously administered, rapid-acting, 
insulin analogs. Late-stage clinical testing of this delivery 
system still appears to be in progress, and a regulatory 
approval has been obtained in Ecuador.
A number of questions still remain about the safety and 
commercial viability of buccal/sublingual delivery systems 
for protein and peptide biopharmaceuticals. Low bioavail-
ability will be a major impediment to commercialization. 
The use of permeation enhancers and enzyme inhibitors to 
address this issue raises concerns about the effects on the 
oral mucosa, particularly when used in combination with 
bioadhesive systems, and long-term toxicology data are 
currently scarce (45). The alternative strategy involving 
chemical modifi cations to improve lipophilicity is not gen-
erally applicable to all peptides and proteins, and remains 
largely unproven. Finally, the limited PK data obtained in 
human studies suggest that buccal/sublingual delivery sys-
tems produce a bolus effect that may not be an appropriate 
pharmacological response for all protein and peptide bio-
pharmaceuticals.
diminish effective dose absorption. The vaginal route is 
gender-specifi c and sexual activity, menstruation, or preg-
nancy, can further complicate administration and impact 
absorption of the biopharmaceutical dose. The buccal/sub-
lingual, nasal, trans-dermal, pulmonary, and oral routes of 
administration are receiving most of the attention by the 
scientifi c community, with some technologies showing 
promise as potentially feasible commercial products. In the 
following sections, each of these non-invasive delivery 
routes will be examined in greater detail.
Buccal/Sublingual/Palatal Administration
The human oral cavity is a readily accessible site for the 
potential non-invasive delivery of protein and peptide bio-
pharmaceuticals, providing a total internal surface area 
covering 0.01 m2, and a highly vascularized mucosa with 
relatively low enzymatic activity (36–39). Administration 
via this region also avoids fi rst-pass hepatic metabolism. 
However, despite these advantages, a multilayered epithe-
lium that is coated with mucus and a constant fl ow of saliva 
are major impediments to achieve effective absorption. 
Permeability of the mucosa in the oral cavity varies, with 
the non-keratinized buccal (cheeks) and sublingual regions 
being most permeable and serving as the primary targets 
for non-invasive delivery systems.
A variety of protein and peptide biopharmaceuticals has 
been evaluated for buccal/sublingual administration using 
both animal models and human subjects (37,38). In the 
research effort by Trapani and colleagues (40), nanoparti-
cles consisting of chitosan and selected cyclodextrins have 
been prepared and characterized in vitro as potential for-
mulations for oral glutathione (GSH) delivery. Their results 
confi rmed that by selecting the most suitable cyclodextrin, 
it was possible to modulate the physicochemical character-
istics of the nanoparticles and their ability to load GSH.
Among the various trans-mucosal sites available, the 
soft-palatal mucosa was also found to be a most convenient 
and easily accessible novel site for the delivery of thera-
peutical agents and achieving systemic delivery as reten-
tive dosage forms, because it has abundant vascularization 
and a rapid cellular recovery time after exposure to stress. 
The palatal mucosa offers several additional advantages 
for controlled drug delivery over extended periods of time. 
The mucosa is well supplied with both vascular and lym-
phatic drainage and both fi rst-pass metabolism in the liver 
and pre-systemic elimination in the GIT are avoided. The 
area is well suited for a retentive device and appears to be 
acceptable to the patient. With the right dosage form, 
design, and formulation, the permeability and the local 
environment of the mucosa can be controlled and manipu-
lated to accommodate drug permeation. Palatal drug deliv-
ery is a promising area for continued research aiming at 
systemic delivery of orally ineffi cient drugs as well as a 
feasible and attractive alternative for non-invasive delivery 
of potent peptide and protein drug molecules (41).
Typical delivery systems evaluated for buccal/sublin-
gual administration of proteins and peptides involve con-
ventional solutions or tablets. Strategies to improve 
absorption include the use of permeation enhancers and 
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fast onset of action, avoidance of fi rst-pass metabolism in 
the liver, increasing drug bioavailability, and less systemic 
side effects (51). The nasal delivery appears therefore to be 
a favourable way to circumvent the obstacles for blood 
brain barrier (BBB), allowing the direct delivery of active 
compounds in the biophase of central nervous system 
(CNS) (52). Intranasal delivery has been used to target a 
wide variety of therapeuticals to the CNS, namely neuro-
trophins (NGF), insulin-like growth factor (IGF-1), neuro-
peptides (hypocretin-1 and exendin), cytokines (interferon 
β-1b) and erythropoietin (52–54). Intranasal administra-
tion of hexarelin, a growth hormone-releasing neuropep-
tide for nose-to-brain targeting, was also enhanced by 
N-tridecyl-beta-D-maltoside as a permeation enhancer. 
Greater hexarelin concentrations in olfactory bulb and 
olfactory tract on the treated side of brain tissues were 
observed in this manner (55). Basic fi broblast growth fac-
tor (bFGF) can also be directly delivered into the brain fol-
lowing intranasal administration, imparting protection 
against brain ischemia/reperfusion in adult rats (56).
When a drug is nasally administered to induce systemic 
effects or to act into CNS, it needs to pass through the 
mucus layer and epithelial membrane before reaching the 
blood stream or pass directly to the CNS. The passage 
across the epithelium may occur by trans-cellular or para-
cellular mechanisms, as described before. The fi rst mecha-
nism includes passive diffusion through the interior of the 
cell and it is especially involved in the transport of lipo-
philic pharmaceuticals. However, it seems that compounds 
with a molecular weight higher than 1 kDa, such as pep-
tides and proteins, are trans-cellularly transported by endo-
cytic processes (57). Since bioavailability of nasally 
administered drugs is particularly restricted by a low drug 
solubility, rapid enzymatic degradation in nasal cavity, 
poor membrane penetration and rapid mucociliar clearance 
(MCC), several approaches have been under study to over-
come such limitations, including the use of prodrugs, enzy-
matic inhibitors, absorption enhancers, development of 
mucoadhesive delivery systems and new pharmaceutical 
forms. Common problems associated with low nasal bio-
availability of drugs, challenges and possible solutions, can 
be found in Table 3.
Chitosan is used in several intranasal pharmaceutical 
forms, including powders, liquids, gels, microparticles and 
microspheres. For some pharmaceuticals, it is well docu-
mented that the addition of chitosan to nasal formulation 
increases drug bioavailability. One of the most studied 
pharmaceuticals for nasal non-invasive delivery is insulin. 
Poly (ethylene glycol)-grafted chitosan (PEG-g-chitosan) 
nanoparticles obtained by ionotropic gelation, adminis-
tered intranasally to rabbits, enhanced the absorption of 
insulin by the nasal mucosa to a greater extent than a sus-
pension of insulin-PEG-g-chitosan and a control insulin 
solution (58). Chitosan also enhanced the brain bioavail-
ability of intranasally administered nerve growth factor by 
a 14-fold increase, when comparing with a preparation 
without chitosan (59).
Cyclodextrins are used as complexing agents to improve 
nasal absorption of pharmaceuticals by increasing both 
drug solubility and stability. Hybrid chitosan-cyclodextrin 
Nasal and Pulmonary Administration
Pulmonary and nasal routes are the other mucosal pathways 
that are attracting considerable attention as alternative 
routes for peptide and protein non-invasive systemic deliv-
ery since they involve very large surface areas and less 
intracellular and extracellular enzymatic degradation (46), 
and thus have demonstrated to be a commercially viable 
alternative to injection administration as evidenced by the 
number of products currently on the market, including (but 
not limited to): calcitonin (3.4 kDa), nafarelin (1.3 kDa), 
desmopressin (1.18 kDa), oxytocin (1.0 kDa) and buserelin 
(1.3 kDa).
Nasal Delivery
Since the very beginning, the nasal route has received 
considerable attention as an ideal site for delivery of both 
low molecular weight compounds and macromolecules, 
due to several characteristics, namely a rapid drug absorp-
tion, ease of administration, and both patient acceptance 
and compliance. Advances in administration device tech-
nologies together with a greater understanding of formu-
lation and dosage form aspects that enable enhanced 
systemic absorption, have provided an enhanced driving 
force for considering the nasal route as an ideal one to 
deliver biopharmaceuticals (47,48). The nasal mucosa 
has therefore emerged as a highly therapeutically viable 
route for systemic drug delivery. In general, among the 
primary targets for intranasal administration are pharma-
cologically active compounds with poor stability in gas-
trointestinal fl uids, poor intestinal absorption and/or 
extensive hepatic fi rst-pass elimination, such as peptides, 
proteins and polar drugs.
The nasal cavity possesses a rather porous endothelium 
and a highly vascularized mucosal membrane that provides 
a large surface area of approximately 0.015 m2 for absorp-
tion. As mentioned previously, nasal administration has the 
added advantage of avoiding hepatic fi rst-pass metabolism. 
However, and despite all these advantages, several barriers 
do exist that need to be successfully overcome to achieve 
suffi cient bioavailability for protein and peptide therapeu-
ticals. Such barriers include: (i) a low membrane permea-
bility of the nasal epithelium, that has been shown to 
display a molecular weight cut off ca. 1 kDa, hence exclud-
ing many (bio)pharmaceutical molecules with molecular 
size greater than 1 kDa (49); (ii) a mucociliary clearance 
mechanism that quickly and effectively renews the mucus 
layer every 15 - 30 minutes, having therefore a high impact 
on the contact time between the formulation and the nasal 
epithelium; and (iii) the presence of various peptidases, 
which cause proteolytic degradation of the protein and 
peptide molecules. Consequently, the bioavailabilities for 
nasally administered protein and/or peptide biopharmaceu-
ticals in human subjects are typically quite low, in the 
range of 1–3% for calcitonin and insulin, for example (50). 
Nevertheless, the intranasal route for brain targeting is 
gaining much attention in the scientifi c community due to 
the particular anatomical and physiological functions of 
the nasal cavity. A number of advantages are particularly 
attractive such as non-invasive rapid systemic absorption, 
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entrapping γ-PGA NPs elicited a potent tumor immunity 
based on TAA-specifi c and long-term cellular immune 
responses. Intranasal vaccination of antigen-entrapping 
γ-PGA NPs was actually considered a non-invasive and 
effective vaccine delivery system.
The primary strategies to improve systemic uptake of 
protein and peptide biopharmaceuticals via nasal non-
invasive delivery include: (i) the use of permeation 
enhancers (50,67) to change the absorptive membrane to 
increase permeability, (ii) the use of excipients/additives 
to increase retention time of the formulation in the nasal 
cavity and/or protect the active agent against enzymatic 
degradation, and (iii) modifi cation of protein and/or pep-
tide chemical structure to increase resistance to enzymatic 
degradation and thus improve absorption. Typical classes 
of permeation enhancers evaluated by researchers include 
surface-active agents such as bile salts, fusidic acid, fatty 
acids, and bile salt-fatty acid mixed micelles that are 
believed to work by the mechanisms described in Table 2. 
In the case of insulin, incorporation of permeation enhanc-
ers increased bioavailability by 8–15% (68,69). However, 
potential barriers for clinical use of enhancers include tox-
icity concerns such as nasal irritation and membrane dam-
aging effects (70). Classical enzyme inhibitors such as 
bacitracin and bestatin have been evaluated as agents to 
improve nasal absorption of peptides, but they have the 
same issue as permeation enhancers in terms of their 
safety for clinical use.
In order to address the rapid removal of pharmaceuticals 
due to the mucociliary clearance mechanism, mucoadhesive 
systems that promote bioadhesive interactions with a 
mucous membrane and therefore increase retention time by 
prolonging the contact between the formulation and absorp-
tion site have been evaluated as a strategy to enhance sys-
temic absorption following nasal administration (71). 
Chitosan, a cationic polysaccharide, has been extensively 
evaluated as a bioadhesive agent to improve nasal absorp-
tion of peptides and proteins including calcitonin, insulin, 
and human growth hormone. In a research effort conducted 
using normal subjects, a bioavailability of 9–15% was 
nanoparticles have also demonstrated their potential for 
enhancing the transport of complex molecules across the 
nasal barrier (60). Hyaluronan is another example of a 
mucoadhesive polymer used in nasal formulations. It has 
demonstrated its ability to improve the brain penetration of 
a hydrophilic peptide via the nasal route (61).
Peptide and/or protein carriers, with average sizes in the 
nanometer range, such as liposomes and nanoparticles, 
exhibit some well-defi ned and delicate characteristics, 
which have created an attractive and effi cient approach for 
pulmonary delivery of pharmaceuticals. Solid lipid nanopar-
ticles (SLNs), introduced in 1991, represent an alternative 
carrier system to traditional colloidal carriers (62). Wang 
and colleagues (63) described that insulin-loaded thiolated 
chitosan nanoparticles considerably improved absorption of 
insulin across the nasal mucosa as compared to non-thio-
lated chitosan nanoparticles. Thiolated chitosan nanoparti-
cles showed a faster swelling and release as compared to 
plain chitosan nanoparticles, which might facilitate diffu-
sion of the encapsulated drug. In vivo evaluations showed 
that after intranasal administration of the insulin-loaded 
thiolated nanoparticles to rats, the plasmatic glucose levels 
of the animals quickly decreased. The glucose levels of 
these animals were similar to those that received insulin 
subcutaneously. Novakovic and co-authors (64) published 
some interesting results, indicating that intranasal delivery 
to a mouse of [D-Leu-4]OB3, a synthetic peptide amide 
with leptin-like activity, with Intravail™, was a more effec-
tive method of peptide administration than injection meth-
ods, and suggested that it may have potential as a novel, 
non-invasive approach to the treatment of obesity and its 
associated metabolic dysfunctions in humans. These results 
were subsequently confi rmed by Lee et al. (65).
Matsuo and co-authors (66) investigated the potential of 
poly(γ-glutamic acid) nanoparticles (γ-PGA NPs) with 
entrapped antigenic proteins as cancer vaccine carriers, to 
be intranasally administered, and determined the anti-
tumor effects and associated immune responses in a mouse 
tumor model. The fi ndings obtained revealed that intrana-
sal administration of tumor-associated antigens (TAA) 
Table 3 Common problems associated with low nasal bioavailability of drugs, challenges and possible solutionsa
Problem Challenge Solution
Poor physicochemical properties of drug 
and/or formulation
Improve physicochemical properties of drug and/or 
formulation
Pro-drugs 
Co-solvents 
Cyclodextrins 
Pharmaceutical excipients 
Novel drug formulations
Enzymatic degradation Reduce drug affi nity to nasal enzymes 
Inhibit nasal enzymes 
Protect drugs from nasal enzymes
Pro-drugs 
Enzymatic inhibitors 
Co-solvents
Low permeability through nasal membrane Increase drug permeability and dissolution 
Modify nasal membrane 
Enhance drug residence time in nasal cavity
Pro-drugs 
Co-solvents 
Absorption enhancers 
Mucoadhesive systems 
Gelling/Viscosifying agents
aFor source details, please refer to references cited throughout the text.
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Pulmonary Delivery
Pulmonary drug delivery is attractive for both local and 
systemic drug delivery as a non-invasive route that pro-
vides a large surface area (78), thin epithelial barrier, high 
blood-fl ow and avoidance of fi rst-pass metabolism in the 
liver (79). Murata et al. (80) investigated the feasibility of 
surface-modifi ed liposomes for the pulmonary delivery of 
the peptide elcatonin (eCT) (a calcitonin derivative used 
as an anti-parathyroid agent). In the study by these 
researchers, chitosan oligosaccharide (oligoCS) and poly-
vinyl alcohol with a hydrophobic anchor (PVA-R) were 
used as surface modifi ers. The effect of liposomal surface 
modifi cation on the behavior of the liposomes for pulmo-
nary administration and potential toxicity were both eval-
uated in vitro and in vivo. The therapeutical effi cacy of 
eCT after pulmonary administration to rats was signifi -
cantly enhanced and prolonged for 48 h after separate 
administration with oligoCS- or PVA-R-modifi ed lipo-
somes. Liposomes modifi ed with oligoCS adhered to lung 
tissues and caused opening of tight junctions, which in 
turn enhanced eCT absorption. On the other hand, PVA-R-
modifi ed liposomes induced long-term retention of eCT in 
the lung fl uid, leading to sustained absorption. These 
researchers have concluded that surface modifi cation of 
liposomes with oligoCS or PVA-R has high potential for 
the effective peptide drug delivery through pulmonary 
administration. Poly (lactic-co-glycolic acid) (PLGA) 
nanospheres coated with chitosan for the pulmonary deliv-
ery of eCT are also an example of the advantages of phys-
ical modifi cations to nanocarriers (81). Powder 
formulations of protein-loaded chitosan nanoparticles 
suitable for pulmonary non-invasive delivery were pre-
pared by spray drying (82). Amidi et al. (83) prepared 
N-trimethyl chitosan (TMC) powder formulations using a 
supercritical CO2 (SC-CO2) drying process for the pul-
monary delivery of insulin. The particles had an average 
aerodynamic diameter of 4 μm, suitable for peripheral pul-
monary deposition. After one-year storage at 4 °C, the par-
ticle characteristics were maintained and the insulin 
structure was largely preserved. In a follow-up study, the 
potential of TMC and dextran powder formulations for the 
pulmonary delivery of insulin was evaluated in diabetic 
rats. Pulmonary administration of TMC-insulin micropar-
ticles, as compared to dextran-insulin microparticles, sig-
nifi cantly enhanced the systemic absorption of insulin, 
with a bioavailability of ca. 95% relative to  subcutaneously 
administered insulin (84).
Lately, much attention has been centered on the pulmo-
nary non-invasive delivery of GLP-1 (Glucagon-like pep-
tide-1) mimetic peptide, in the treatment of type II diabetes. 
Qian et al. (85) assessed the feasibility of delivering BMS-
686117 (an 11-merGLP-1 receptor peptide agonist) to the 
lung in rats via intratracheal administration. The PK pro-
fi les of three spray-dried, prototype inhaled powder formu-
lations, 80/20 BMS-686117/trehalose (I), 100% 
BMS-686117 (II), and 20/80 BMS-686117/mannitol (III), 
as well as a lyophilized BMS-686117 powder, were com-
pared to intravenously and subcutaneously administered 
peptide. The spray-dried formulations were mostly spheri-
cal  particles with a narrow particle size distribution 
reported when insulin was administered in a chitosan solu-
tion (50). In the case of peptides such as leuprolide and 
salmon calcitonin, nasal bioavailabilities of approximately 
20% have been reported in clinical trials (72). The absorp-
tion-enhancing mechanism of chitosan is believed to be due 
to a combination of mucoadhesive properties and opening of 
the tight junctions. Chitosan is biocompatible, an important 
attribute it shares with compounds such as cyclodextrins and 
phospholipids, and from a practical perspective, it is likely to 
be safer for human use compared to other permeation 
enhancers. Formulation and dosage form aspects that can 
affect the site of deposition within the nasal cavity are a key 
consideration for nasal delivery. The site of deposition can 
affect absorption due to the differences in the permeability 
and residence time of the anterior and posterior portions of 
the nose. A wide variety of dosage forms such as nasal drops, 
sprays, gels, powders, or microspheres, are available for 
administering (bio)pharmaceuticals by the nasal route, and 
these options need to be carefully evaluated because the type 
of dosage form can affect where the formulation is deposited 
in the nasal cavity and, in turn, affect the systemic absorp-
tion. For example, the bioavailability of nasally adminis-
tered desmopressin was signifi cantly increased in a spray 
formulation compared to drops (73), most likely because the 
spray formulation delivered the peptide molecules to the 
posterior region of the nose (as compared to the drops), 
which is highly rich in ciliated cells and has a larger surface 
area, thereby contributing to increased absorption. Modula-
tion of viscosity properties via addition of viscosity-enhanc-
ing agents has also been shown by several researchers to 
increase systemic absorption (74). Powder dosage forms can 
also offer several advantages over solutions for protein and 
peptide nasal non-invasive delivery. For example, a bio-
availability of ca. 10% calcitonin was observed in human 
subjects following administration as a nasal powder contain-
ing microcrystalline cellulose (a cellulosic polymer) (75). 
The use of cyclodextrins has been also investigated in clini-
cal studies for the nasal delivery of several peptide and pro-
tein (bio)pharmaceuticals such as calcitonin, glucagon, 
recombinant human granulocyte colony stimulating factor 
(rh-GCSF) and insulin. With an intranasal insulin/dimethyl-
β-cyclodextrin powder formulation, average absolute bio-
availabilities of ca. 3.4% and ca. 5.1% were obtained in 
healthy volunteers and patients with diabetes respectively 
(76). The nasal route can therefore be a viable option for the 
non-invasive delivery of proteins and peptides. However, 
the collective knowledge gained indicates that although it 
may be feasible to deliver smaller peptides with acceptable 
bioavailability levels, for larger peptide molecules (with 
more than 20 aminoacid moieties) acceptable systemic 
absorption typically can only be achieved with the use of 
permeation enhancers (77). A number of protein and peptide 
molecules such as insulin, human growth hormone, and 
human β-interferon are currently in early clinical develop-
ment for delivery via the nasal route, and the experience 
gained from these studies and other ongoing research works 
in this fi eld should eventually help to establish in a near 
future, whether the nasal route can be successfully used to 
deliver a broad range of proteins and peptides with accept-
able safety and effi cacy.
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peptide molecules must possess an appropriate aerody-
namic diameter in the range of 1–3 mm (90,91). The aero-
dynamic diameter can be expressed in simple mathematical 
terms as the product of a particle geometric diameter mul-
tiplied by the square root of its density. Particles with 
aerodynamic diameters that are too large will become 
lodged in the nasopharynx region, whereas those that are 
too small are exhaled. Most developments in inhalation 
technology are based on optimized formulation and device 
combinations that are capable of effi ciently and reproduc-
ibly deliver particles with the correct size to the deep lung 
region.
Technologies currently under development for deliver-
ing protein and peptide biopharmaceuticals involve either 
liquid formulation or dry powder inhaler systems (92,93). 
Liquid-based systems atomize solution formulations into 
fi ne inhalable droplets via mechanical means through a 
jet, ultrasonic atomization, or electrospray (94,95). Each 
delivery system (92) employs particle engineering 
approaches using various excipients (e.g., aminoacids, 
carbohydrates, and/or phospholipids) included in the for-
mulation and specifi c spray drying process conditions to 
achieve the desired properties of the fi nished powder (96–
98). Processing conditions are also controlled to produce 
particles having shape and surface morphologies that 
minimize cohesive and adhesive forces enabling effi cient 
dispersion. The ability to escape clearance by alveolar 
macrophages is an additional claimed advantage of the 
large particle design strategy (98–100). Alternative design 
strategies for protein and peptide pulmonary delivery sys-
tems have been described in the literature. Studies have 
been reported evaluating the inclusion of permeation 
enhancers and enzyme inhibitors in formulations as a 
means to improve absorptive potential (30,101). How-
ever, the safety implications with any chemical agent that 
potentially modifi es normal lung physiology must be con-
sidered especially for chronic treatment situations. A 
strategy involving a carrier-based formulation utilizing 
self-assembling diketopiperazine derivatives that can 
encapsulate protein and/or peptide moieties into micro-
spheres (Technosphere™) has also been proposed by sev-
eral researchers (102,103). The resulting particles are 
harvested and dried to produce a powder that can be 
administered with a passive inhaler device. A delivery 
system for insulin based on this design has been evalu-
ated in human proof-of-concept studies (102,103). How-
ever, some concerns with this methodology include the 
long-term safety of the diketopiperazine derivatives that 
appear to act as an absorption enhancer, and the addi-
tional costs associated with including such compounds in 
the formulation. Another approach involves a formulation 
containing micronized crystalline insulin produced by jet 
milling, to achieve the appropriate geometric size range 
for inhalation, blended with a lactose monohydrate car-
rier. Dispersion of the dry powder is achieved with an 
electromechanical, breath-actuated device. This insulin 
delivery system, referred to as Spiros™, has also been 
evaluated in human clinical trials (104).
The feasibility of pulmonary administration for a wide 
variety of proteins and peptides has been evaluated in both 
between 2–10 µm, which are better suited for inhalation 
delivery than the lyophilized, irregular shape powder, with 
a wide particle size distribution between 2–100 µm. Proto-
type III exhibited the best physical characteristics and in 
vivo  performance, with a bioavailability of ca. 45% relative 
to subcutaneous administration. The study described by 
Qian et al. (85) clearly demonstrated that pulmonary deliv-
ery is a promising, non-invasive route, for the administra-
tion of BMS-686117.
Patton (86) reviewed in detail the specifi c anatomical, 
histological, and physiological features associated with 
the human respiratory tract and the suitability of the 
lungs as an organ for the systemic delivery of pharma-
ceuticals. In particular, the lungs are an attractive target 
for the systemic non-invasive delivery of protein and 
peptide molecules due to (i) avoidance of hepatic fi rst-
pass metabolism, (ii) a large absorptive surface area of 
the alveolar region (ca. 100 m2), (iii) a relatively low 
enzymatic activity, (iv) a highly vascularized mucosa 
and (v) a thin epithelial (0.1–0.2 mm) barrier that is not 
ciliated and is free of mucus. Notwithstanding these 
advantages, a signifi cant impediment to the pulmonary 
administration is the physical delivery of the active bio-
pharmaceutical to the site of absorption (deep lung, alve-
olar region), which involves passing through many 
bifurcations of the lung airways. Simply achieving the 
required deposition will not guarantee effective absorp-
tion, since the transport process into the systemic circu-
lation involves passage through a series of additional 
barriers including (but not limited to) (i) surfactant layer, 
(ii) epithelial surface lining fl uid, (iii) epithelial mono-
layer, (iv) interstitium and basement membrane, and (v) 
capillary endothelium. The absorption effi ciency can 
also be signifi cantly reduced by natural phagocytotic (via 
macrophage) clearance mechanisms designed to elimi-
nate inhaled foreign particles from the lungs. The exact 
mechanism of absorption is not fully understood, 
although paracellular and trans-cellular mechanisms 
have been postulated depending upon molecular weight 
of the protein or peptide moieties (86).
A pulmonary delivery system for the local administra-
tion of the enzyme rhDNase used in the treatment of cystic 
fi brosis (87) is now commercially available. However, 
until now, no products for systemic delivery of protein or 
peptide biopharmaceuticals via the pulmonary route had 
received regulatory approval. This is partly due to limita-
tions in currently available nebulizers, pressurized 
metered-dose and dry powder inhaler systems (88), that 
are either not suitable due to poor formulation stability 
and ineffi ciency and/or cannot reproducibly deliver such 
molecules to the site of absorption to achieve suffi cient 
drug levels in the systemic circulation. Nevertheless, 
intense research efforts in the area of inhalation adminis-
tration have produced a greater understanding of the aero-
dynamic properties of particles that are important for their 
deep lung deposition (89), resulting in signifi cant develop-
ments in protein and peptide pulmonary delivery systems 
that appear to have overcome some of the defi ciencies in 
current inhaler designs. To achieve effective deposition 
into the alveolar region, particles containing protein or 
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pulmonary delivery system capable of producing a sustained 
release profi le is developed. One report describes the prepa-
ration of large porous particles containing insulin and prot-
amine as a potential sustained release pulmonary formulation 
(120). The pulmonary administration of this formulation to 
rats produced sustained plasma insulin levels similar to 
those obtained following subcutaneous injection.
Trans-dermal Administration
Trans-dermal delivery is a prospective route of administra-
tion for peptide and protein biopharmaceuticals. However, 
physical and/or chemical enhancement technologies are 
necessary to make possible the successful delivery of these 
hydrophilic molecules (121). Microporation technologies 
offer an attractive approach to deliver both peptide and 
protein molecules. Electrically assisted technologies such 
as iontophoresis and electroporation have also been useful 
for the delivery of these (macro)molecules. Low-frequency 
sonophoresis has also enabled the trans-dermal delivery of 
both peptides and proteins. Formulation approaches have 
also been used for the trans-dermal delivery of smaller 
peptides. Trans-dermal delivery has the advantages that 
skin has a large and accessible surface area (1–2 m2) with 
relatively low enzyme activity; it avoids fi rst-pass hepatic 
metabolism and has the potential to provide sustained 
delivery of pharmaceuticals (122). However, skin also 
serves as an extremely effective permeability barrier, a 
property conferred by the thin (0.015 m) outermost layer of 
epidermis known as the stratum corneum. As a result, 
trans-dermal transport by passive diffusion is limited to 
low molecular weight (less than 0.5 kDa) and highly lipo-
philic pharmaceuticals and, indeed, all the marketed trans-
dermal products to date fall into this category (123). The 
trans-dermal route for non-invasive systemic delivery of 
protein and peptide molecules has been hindered by the 
extremely low permeability of skin to these high molecular 
weight and typically hydrophilic molecules, and to achieve 
therapeutically useful systemic drug levels, permeation 
needs to be enhanced. Several approaches have been 
explored that provide additional driving force in the form 
of electrical (iontophoresis) (124,125) or ultrasound (sono-
phoresis) (126) energies, structural perturbation of stratum 
corneum (e.g., electroporation, thermal microporation, 
microneedles) (127,128), penetration enhancers (129,130), 
or a combination of these strategies. A summary of 
enhancement technologies for the trans-dermal delivery of 
peptides and proteins can be found in Table 4.
A variety of chemical penetration enhancers with or 
without protease inhibitors or colloidal vehicles (lipo-
somes) have been investigated for their potential to 
enhance the skin permeability to peptides and proteins 
(129,130). One notable case is the use of the so-called 
Transferosomes™, ultrafl exible liposomes containing a 
mixture of soybean phosphatidylcholine and sodium 
cholate, which are thought to reversibly create intercel-
lular hydrophilic pathways through the skin to facilitate 
transport (151,152). Insulin-loaded Transferosomes™ 
applied epicutaneously to human volunteers have been 
shown to result in a glucodynamic response comparable 
animal models and in some human proof-of-concept stud-
ies (88,105,106). A wide range of bioavailabilities (from 
less than 1% up to 95%) has been reported. An insulin pul-
monary delivery system (Exubera™) consisting of a dry 
powder formulation composed of small geometric diame-
ter particles produced by spray drying and utilizing a 
mechanical device for dispersion has won regulatory 
approval in both the USA and Europe. Data evaluating this 
system in numerous clinical trials, including large-scale 
studies involving both patients with Type-I or Type-II dia-
betes over extended periods of use, have been published 
(107–111). The other dry powder technology utilizing for-
mulations composed of geometrically large, but low-den-
sity, particles that are dispersed with a passive device is 
being developed for pulmonary administration of insulin 
(93). Both safety and effi cacy results evaluating this deliv-
ery system in patients with Type-I diabetes have also been 
reported (112). A liquid-based, microprocessor-controlled 
insulin delivery system identifi ed as AERx™ is advancing 
in clinical trials involving both patients with Type-I or 
Type-II diabetes, and the results of these studies have also 
been published (113–116). Another liquid-based, breath-
actuated, insulin delivery system (Aerodose™) is also pro-
gressing in development, and evaluations conducted in 
patients with Type-II diabetes have been reported (95,117). 
Based on all the published information pertaining to clini-
cal trials, some generalizations about pulmonary insulin 
administration can be made (118,119). The PK profi le of 
inhaled insulin is characterized by a faster onset when 
compared to the subcutaneous administration of insulin 
solution formulations, and is at least as fast as rapid-acting 
insulin analogs. The duration of action is intermediate 
between that of subcutaneously administered rapid-acting 
insulin analogs and regular insulin. Estimated bioavail-
abilities are typically in the range of ca. 10–20% relative to 
insulin administered via subcutaneous injection, although 
higher values have been reported in studies involving the 
Technosphere™ technology.
The overall bioavailability of a delivery system is infl u-
enced by various potential losses of the formulation in, for 
example, the device, packaging walls, mouth, oropharynx, 
or by exhalation. Intrapatient variability in PK and PD 
responses is low and similar to subcutaneously administered 
insulin. In special patient populations such as smokers, 
absorption of insulin is signifi cantly greater, and different 
smoking patterns can theoretically infl uence dose require-
ments of inhaled insulin (115). This phenomenon, likely the 
result of cellular and/or physiological alterations in the 
lungs, could have important pharmacological implications 
for delivery of protein and peptide molecules in general. 
Other studies conducted in elderly subjects, asthmatics, or 
individuals with acute respiratory tract infections, also 
showed changes in PK/PD responses (119). The successful 
regulatory approval for pulmonary administration of insulin 
will likely open the door for other biomolecules to be con-
sidered for delivery via this route. Although the PK profi le 
reported for inhaled insulin seems appropriate to meet pran-
dial insulin requirements, it will not address basal insulin 
needs. In certain treatment regimens, an injection of a long-
acting (basal) insulin preparation will be required unless a 
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skin, however, cannot access LCs in the epidermal layer, 
because the stratum corneum acts as a physical barrier to 
substance penetration (154). Huang et al. (155) established 
that the interaction between metal-based nanoparticles 
(gold-NPs) and the skin barrier leads to enhancement of 
skin permeability and effectively prompts percutaneous 
absorption of the co-administered proteins. The benefi t of 
this co-delivery method is that it does not require “loading” 
of the bioactive molecules into the nanoparticulate system, 
but simply in a physical mixture instead. Consequently, a 
compromise in activity can be achieved for both protein 
drugs and nanoparticles due to the exclusion of complicated 
drug-loading processes. Such co-delivery effect highlights 
a new strategy for percutaneous protein delivery with obvi-
ous advantages in terms of simplicity and cost-effective-
ness. It provides a promise in achieving self-administered 
to subcutaneously administered Ultralente preparation 
Ultratard™, albeit at approximately twice the insulin 
dose. With a single application of Transferosomes™ to 
patients with Type-I diabetes, normoglycemia has been 
maintained for 16 hours (153). This approach has also 
been successfully demonstrated with other polypeptides 
such as interferons α, β, and γ, calcitonin and superoxide 
dismutase in preclinical experiments (152).
The skin acts not only as a physical barrier but also 
as an immunological barrier, being enriched with various 
immunocompetent cells such as Langerhans cells (LCs), 
keratinocytes, dermal dendritic cells, and mast cells (153). 
In particular, LCs play a critical role as potent antigen- 
presenting cells against external antigens. Direct delivery 
of antigens to the LCs is expected to induce an effective 
immune response. Antigenic proteins applied to the bare 
Table 4 Trans-dermal enhancement technologies for non-invasive delivery of peptides and proteins
Microporation technology
Microporation technology 
Electrically assisted 
techniques
Sonophoresis
Formulation 
approachesTechnology Microneedles
Thermal 
micropora-
tion
Radio 
frequency 
ablation
Laser 
Ablation Iontophoresis
Electropora-
tion
Principle Micron-sized 
needles 
which 
breach the 
stratum 
corneum to 
create 
microchan-
nels through 
skin.
Creation of 
microchan-
nels in skin 
can also be 
achieved 
when an 
array of 
electrically 
resistive 
fi laments is 
applied.
Electric 
current in 
the range of 
radio 
frequency 
(100–500 
kHz) is used 
to create 
microchan-
nels in skin.
Microporation 
of skin can 
also be 
achieved 
with the 
help of 
medical 
lasers.
Application 
of small 
amounts of 
physiologi-
cally 
acceptable 
current to 
drive drug 
molecules 
into and 
across skin.
Use of high 
voltage 
(100–
1000 V) 
electric 
pulses for a 
very short 
duration of 
time 
(several 
microsec-
onds to 
millisec-
onds) to 
permeabi-
lize skin.
The use of 
ultrasound to 
drive 
molecules 
into and 
across skin.
Used in 
conjunction 
with physical 
enhancement 
techniques 
for assisting 
trans-dermal 
delivery of 
proteins, 
such as 
nanotechnol-
ogy- based 
carriers 
(liposomes 
and 
nanopar-
ticles).
The pros Offers elegant, effective and painless delivery of peptides 
and proteins.
Non-invasive 
technique, 
offers 
modulated 
and 
controlled 
delivery.
Used for 
electroche-
motherapy 
and gene 
delivery.
Low frequency 
sonophoresis 
can deliver 
macromol-
ecules into 
and across 
skin.
Simple 
approach 
without need 
of equipment.
The cons Pore closure dynamics must be taken into account for 
planning effective drug delivery regimen and avoiding 
any potential infection risks.
Delivery 
limited to 
molecular 
weight of 
 ≈ 13 kDa.
Safety of 
using this 
enhance-
ment 
technique 
for drug 
delivery 
should be 
accessed.
Convenient 
hand held 
technologies 
should be 
developed.
Delivery 
limited to 
low 
molecular 
weight 
peptides or 
proteins.
References (131–142) (137,143,144) (145–147) (148,149) (129,130,150)
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 examined the potential of poly(D,L-lactic acid) (PLA) 
nanoparticles as vectors for antigen delivery via the trans-
cutaneous route. Using a double emulsifi cation process, oval-
bumin (OVA)-loaded PLA nanoparticles induced effi cient 
cytokine responses. In vitro re-stimulation of cultured sple-
nocytes with OVA elicited a little higher levels of IFN-γ and 
signifi cantly higher levels of IL-2 in mice, compared to those 
immunized with OVA in solution. Nanoscopic therapeutical 
systems that incorporate biocompounds, such as protein and 
peptides, are emerging as the next generation of nanomedi-
cines, aiming at developing therapeutical effi cacy of pharma-
ceuticals. The delivery of peptides and proteins intended for 
therapeutical purposes poses unique diffi culties in their 
encapsulation, especially because most of them possess a sig-
nifi cant hydrophobic component and thus display a low ten-
dency to adsorb onto surfaces (150,162). Such adsorptive 
behaviour can lead to distinct losses in the amount of macro-
molecule available for delivery.
The design of new formulations, particularly lipid-
based nanoscale carriers, appears promising for the dis-
ruption of stratum corneum through the nano-bio 
interaction of colloidal carriers with skin lipids, protection 
of proteins and peptides from the external milieu, and 
maintenance of long-term activity. The lipid-based vesi-
cles of liposomes, especially elastic liposomes, may 
change the bioactive permeation kinetics due to an 
impaired barrier function of the stratum corneum, which is 
helpful for skin penetration. Results obtained by Li and 
colleagues (150,162) highlight the nanoscale formulation, 
fl exible liposome, as a promising carrier for the trans-
cutaneous delivery of antigen proteins. New studies have 
demonstrated that non-invasive trans-dermal iontophore-
sis can be used to deliver signifi cant amounts of a structur-
ally intact, functional protein, across the skin. In fact, 
results gathered by Dubey and Kalia (144) demonstrated 
the feasibility of using trans-dermal iontophoresis to non-
invasively deliver an intact functional protein (such as 
ribonuclease A) across the skin.
Ultrasounds of low-frequency have also been used to 
deliver insulin, γ-interferon, and erythropoietin in in vitro 
studies (164), although validation of this approach in 
humans has not yet occurred. Other trans-dermal 
approaches that have been explored are the so-called mini-
mally invasive technologies that physically circumvent the 
stratum corneum either by creating transient micropores by 
heat (thermal microporation) or the use of microneedles 
(128), or ablation of stratum corneum with a laser 
(165,166). Eppstein and colleagues (167) reported the use 
of a thermal microporation process to deliver insulin Lis-
pro to human test subjects. The MicroPors™ technology 
employed in their research work uses electrical current to 
heat an array of small diameter wires pressed against the 
skin, resulting in the creation of pores in the stratum cor-
neum. Basal serum levels of insulin Lispro were reached 
with this delivery system, but the sampling period only 
covered three hours. Similar to the minimally invasive 
approaches is electroporation, which involves application 
of high-voltage electrical pulses to create new low-resis-
tance pathways through the stratum corneum (127,146). 
Despite all the efforts in this area, there are currently no 
trans-cutaneous immunization, and may especially benefi t 
those areas underserved for medical care.
The safe and effective delivery of peptides has also been 
successfully demonstrated in human subjects using ionto-
phoresis, a technique that uses mild electric current to facili-
tate transport of molecules across the skin (125). 
Iontophoresis works primarily by a combination of two 
forces, electrorepulsion of charged drug molecules away 
from the electrode and into the skin, and electroosmosis, a 
convective solvent fl ow in the direction of the counter-ion 
transport. In general, cationic proteins and peptides are 
delivered more effi ciently than anionic molecules, because 
electroosmosis works in the same direction as electromigra-
tion for cationic species, whereas it works against it for 
anionic species. Iontophoretic delivery of the luteinizing 
hormone-releasing hormone (LHRH) analog leuprolide has 
been demonstrated in clinical studies in human subjects 
(125,156,157) and showed an increase in luteinizing hor-
mone levels comparable to those following a subcutaneous 
injection. Although this proof-of-concept demonstration 
occurred several years ago, it is not evident if this approach 
is anywhere close to commercialization for peptide drugs. 
The trans-dermal delivery of insulin remains a signifi cant 
challenge due to low permeation rates at therapeutically use-
ful rates. The delivery of insulin achieved in animal models 
appears to be far below the daily basal insulin needs for 
humans to be practical, and commercial viability remains 
questionable (118,158). Chen and colleagues (137) report 
unilamellar nanovesicles with membrane thickness of ca. 
3–5 nm and an entrapment effi ciency of ca. 89.05±0.91%, 
which can be driven by iontophoresis for enhancing trans-
dermal delivery of insulin through microneedle-induced 
skin microchannels. The permeation rates of insulin from 
positive nanovesicles driven by iontophoresis through skin 
with microneedle-induced microchannels were 713.3 times 
higher than that of its passive diffusion. This approach offers 
a new strategy for the non-invasive delivery of peptides with 
large molecular weights using nanovesicles. Su et al. (159) 
reported a novel multilayer fi lm in which a hydrolytically 
degradable loaded protein and oligonucleotide was incorpo-
rated for trans-cutaneous delivery. By applying a solid-in-oil 
(S/O) nanodispersion, Tahara et al. (160) successfully 
achieved trans-cutaneous immunization (TCI) without the 
use of any skin pre-treatment or adjuvant. The oil-based 
nanodispersion of hydrophilic drugs has effectively 
enhanced the permeation of proteins into the skin. TCI tar-
geting the LCs of the epidermal layer is a promising needle-
free, easy-to-use, and non-invasive vaccination method. 
Matsuo et al. (161) developed a hydrogel patch formulation 
to promote the penetration of antigenic proteins into the stra-
tum corneum. These researchers investigated the character-
istics of the immune responses induced by this vaccination 
method and the vaccine effi cacy of TCI using a hydrogel 
patch containing tetanus and diphtheria toxoids.
Nanoparticles were shown to be promising carriers for 
trans-cutaneous vaccines. Due to the nano-bio interaction 
with skin lipids and the consequent induction of transient and 
reversible opening of the stratum corneum, encapsulation 
of antigens in nanoparticles is effective to enhance the 
trans-cutaneous delivery (162). Mattheolabakis et al. (163) 
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barriers and short half-life in the blood stream (14). The 
development of new drug delivery systems suitable for 
protein/peptide drugs, based on nanoencapsulation, has 
become therefore a major area of research, since it has 
been observed that a greater number of nanoparticles cross 
the GIT epithelium than do microparticles (14).
Several researchers reported that water-soluble chitosan 
nanoparticles enhance and prolong the intestinal absorp-
tion of bovine serum albumin, which makes them a poten-
tial protein delivery system (174). Chitosan nanoparticles 
containing an anionic cyclodextrin (SBE7μ−β-CD) appear 
to be extremely interesting as possible oral GSH carriers, 
since they combine improved GSH loading with the capac-
ity to promote GSH transport through the intestine, as 
observed in a frog intestinal sac model. Another tight junc-
tion peptide (TJP) was shown to provide a dramatic 
improvement in drug permeation across epithelial tissue of 
salmon calcitonin, parathyroid hormone 1-34 (PTH1-34), 
and peptide YY 3-36 (PYY3-36). In addition, when the for-
mulation containing this TJP was administered intranasally 
in rabbits, a dramatic increase in bioavailability was 
observed (175). Oral delivery technology based on hydro-
gels that exhibit reversible, pH-dependent swelling behav-
ior appears to protect insulin from enzymatic degradation 
in a gastric milieu and releases it following an exposure to 
intestinal environment. The swelling of the hydrogel in the 
intestinal fl uid leads to bioadhesion onto the intestinal wall. 
This technology demonstrated relatively high (ca. 8%) 
bioavailability in rats (176,177).
Nano-sized particles appear to be a highly promising 
solution for (non-invasive) peptide and/or protein adminis-
tration, due to several characteristics namely (i) their 
intrinsic versatility for drug formulations, (ii) sustained-
release properties, (iii) subcellular size and (iv) tissue and 
cell biocompatibility, and have therefore consistently been 
receiving more attention than do liposomes because of 
their therapeutic potential and greater stability in biologic 
fl uids as well as during storage (14,178,179). To target the 
nanoparticles encasing protein and/or peptide moieties to a 
specifi c cell and/or site, advances in nanotechnology 
involve the decoration of nanoparticle surface with target-
ing moieties such as monoclonal antibodies or other com-
pounds such as transferrin, lectin, or avidin (180,181).
Delivery through the oral route is, undoubtedly, the most 
attractive way for administration of any (bio)pharmaceuti-
cals, but the development of commercially feasible sys-
tems for protein and peptide (bio)pharmaceuticals is a 
formidable challenge, mainly due to the fact that the GIT 
has evolved to effi ciently degrade and assimilate nearly all 
of the dietary protein. Therefore, adding to the fact that 
proteins and peptides exhibit intrinsically low permeabili-
ties, the fundamental problem lies in delivering the intact, 
(bio)active molecule to the site of absorption and protect-
ing it from the onslaught of enzymatic degradation. A pro-
tein or peptide moiety that has been ingested has to resist 
not only the (highly) acidic pH environment and presence 
of proteolytic enzymes in the stomach, as gastric emptying 
occurs, but also the pancreatic enzymes launched into the 
small intestine (duodene) that continue the hydrolysis pro-
cess with high effi ciency. Besides constituting a signifi cant 
commercially available trans-dermal delivery systems for 
protein or peptide biopharmaceuticals. Among active trans-
dermal technologies, iontophoretic delivery devices are in 
late-stage clinical trials with small non-peptide therapeu-
tics (125). Although much effort has been spent on insulin, 
in general small and potent peptides are the best candidates 
for exploring the iontophoretic delivery option. Iontopho-
retic delivery has the advantage of achieving sustained and 
controllable delivery of peptides that makes it particularly 
attractive for molecules with a narrow therapeutical index, 
but in practice overcoming low bioavailability using a 
device at a reasonable cost is a key challenge. Although 
some of the minimally invasive technologies appear to be 
promising, the safety of these approaches, especially under 
chronic use conditions, remains largely unknown. Skin 
irritation is a concern even for passive trans-dermal patches 
(168), and permeation enhancers further increase the risk 
of skin toxicity (130). The potential effect of common per-
meation enhancers such as alcohols and surfactants on the 
higher order structure and physical stability is an additional 
challenge for protein and peptide therapeuticals.
Oral Administration
The oral route is the most frequently used way for adminis-
tering drugs, although it may have serious inconveniences for 
peptide and protein biopharmaceuticals. The primary reasons 
for this are that during the transit through the GIT, these mol-
ecules are exposed to enzymatic degradation, and they also 
have to overcome the mucus layer and epithelial absorption 
barriers. The use of nanoparticles for encapsulating peptide 
and protein molecules is a promising approach (1) for pro-
tecting these biological molecules from enzymatic degrada-
tion. In addition, it has been stated that particles smaller than 
500 nm can pass across the intestinal mucus layer by endocy-
tocis. Formulations including chitosan, a classical permeabil-
ity enhancer that demonstrates mucoadhesive and tight 
junctions opening functionalities, has been most often inves-
tigated (169,170). Several experimental approaches have 
been related to identify tight junction targets that are most 
appropriate for pharmacological manipulation in order to 
enhance paracellular delivery. Tight junctions are composed 
of three major types of integral membrane proteins, viz. 
occludin, claudins and junctional adhesion molecules, and 
the claudin family currently appears to be a confi rmed poten-
tial target (23). Alginate-chitosan nanoparticles administered 
orally to diabetic rats were found to be effective for oral insu-
lin delivery (171).
Protein and peptide (bio)pharmaceuticals are gathering 
increasing interest within the pharmaceutical industry (14), 
not only due to a better understanding of their role in phys-
iopathology, but also because recombinant DNA technol-
ogy is nowadays a well-established technology that allows 
large scale production of therapeutically important (recom-
binant) proteins (172). However, if oral administration is 
sought (14,173), two major drawbacks of such macromo-
lecular (bio)pharmaceuticals lies in the fact that (i) they are 
easily hydrolyzed by proteolytic enzymes ubiquitous in the 
GIT, thereby leading to low bioavailability, and (ii) they 
possess an intrinsically low permeability across biological 
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junctions (191). The safety of these agents in both animal 
and human subjects has been established, at least in acute 
dosing situations (191). The fi rst strategy, encompassing 
the delivery agent technology mentioned above, has been 
evaluated in human subjects for salmon calcitonin 
(197,198), insulin (191,199), and the non-peptide macro-
molecule drug heparin (200,201). In a Phase 1 clinical 
study, the oral absorption of salmon calcitonin was demon-
strated in healthy male volunteers using a tablet formula-
tion containing an unidentifi ed caprylic acid derivative as 
the delivery agent (198), but the bioavailability attained 
was only ca. 1%. The formulation administered orally was 
well tolerated and produced all biological effects of calci-
tonin. In another Phase 1 clinical study, absorption of orally 
administered insulin was clearly demonstrated by a reduc-
tion in fasting plasma glucose levels (191). Although the 
exact details concerning bioavailability following oral 
administration were not reported by these authors, based 
on PD response the bioavailability relative to subcutaneous 
injection is likely to be ca. 10%. The potential of this tech-
nology to deliver the parathyroid hormone has also been 
reported in a primate study (202), resulting in a bioavail-
ability of ca. 2% relative to subcutaneous administration 
via injection. The second strategy mentioned involves 
chemical modifi cation of the protein or peptide moiety by 
attaching amphiphilic residues composed of both lipophilic 
alkyl groups and hydrophilic polyethylene glycol units to 
specifi c sites on the surface of the protein or peptide mol-
ecule (203). Besides improving stability against enzymatic 
degradation, this modifi cation improves drug solubility in 
formulations that enhance absorption through the intestinal 
mucosa. An added advantage of this technology lies in the 
potential to increase circulation half-life by simply design-
ing the covalent modifi cation in a way that specifi c hydro-
lysis in vivo results in a pegylated therapeutical. An insulin 
derivative, hexyl-insulin monoconjugate 2 (HIM2), based 
on this technology has been evaluated by several research-
ers in clinical studies in human patients with Type-I diabe-
tes (203,204), and a dose-dependent decrease in blood 
glucose has been clearly observed. Although no bioavail-
ability studies have been conducted, given the limited rel-
evance of traditional PK studies due to both hepatic uptake 
of orally administered insulin and the resulting effects on 
glucose homeostasis, an ‘‘apparent’’ bioavailability of 
approximately 5% has been suggested (203). The results 
obtained with this delivery system are apparently encour-
aging enough to warrant further development and clinical 
investigations in Type-II diabetic patients (205), at the 
same time that the utility of this technology to orally deliver 
a modifi ed form of calcitonin (CT-025) has also been 
 demonstrated in healthy volunteers (206).
Ocular Administration
The main problems of conventional ocular therapy are short 
residence time, drug drainage and frequent instillation. 
Nanoparticles seem to be promising vehicles for designing 
new controlled delivery systems to improve the ocular 
 bioavailability of drugs for ophthalmic diseases (207). 
A review by Paolicelli and co-workers (208) provides an 
barrier to permeability, enterocytes present in the epithe-
lium of the small intestine also present another enzymatic 
barrier both in the form of various enzymes associated with 
the brush border membrane as well as those contained in 
the mucus and the cytoplasm (182). Absorbed protein or 
peptide moieties are subject to further degradation via 
hepatic metabolism. In spite of these challenges, formida-
ble in nature, the attractiveness of the oral route has 
prompted exploration of an incredibly diverse set of strate-
gies aiming at delivering proteins and peptides (183–191). 
Such strategies include (i) use of permeation enhancers, 
(ii) addition of enzyme inhibitors, (iii) addition of mucoad-
hesives, (iv) use of multifunctional matrices that simulta-
neously incorporate strategies (i), (ii), and (iii), (v) addition 
of enteric coatings that confer protection against the acidic 
environment of the stomach, (vi) micro- and nanoencapsu-
lation (within liposomes, microspheres, and nanoparticles), 
(vii) addition of pH-sensitive polymers, (viii) use of micro-
emulsions (both simple and multiple ones), (ix) use of spe-
cifi c carriers (delivery agents), and (x) protein modifi cation 
either to simply enhance permeability or to exploit specifi c 
transporters.
The use of liposomes to vehiculate protein drugs through 
the GIT was considered promising, because of their ability 
to protect the encapsulated drugs from enzymatic and pH 
degradation, and also to improve absorption. Nevertheless, 
poor success has been achieved, due to poor stability under 
the diverse physiological conditions typically found in the 
GIT. However, mucoadhesive liposomal systems prepared 
by coating lipid suspensions with mucoadhesive polymer 
solutions, such as mucin, showed some success in intesti-
nal absorption of protein drugs, for example, insulin (192). 
This approach can be taken further by the use of a protease 
inhibitor as a coater: Werle and co-workers have investi-
gated the effi cacy of liposomes coated with the polymer-
protease inhibitor conjugate chitosan-aprotinin for oral 
peptide delivery (193).
In particular, one delivery system that uses a “carrier” 
(or “delivery agent”) to facilitate macromolecular absorp-
tion, and another delivery system that uses covalent modi-
fi cation of the therapeutical protein moiety, appear most 
promising and are currently receiving most attention from 
the (bio)pharmaceutical industry. In the fi rst strategy, a 
delivery agent (an aminoacid derivative or a small peptide-
like compound) is selected from a library of molecules and 
used in combination with the therapeutical protein or pep-
tide moiety (194). Although the exact mechanism by which 
delivery agents facilitate the macromolecular transport 
remains essentially unknown, it has been proposed by sev-
eral researchers that these (mainly hydrophobic) agents 
bind non-covalently and reversibly to protein and peptide 
moieties and thus increase their lipophilicity (191). Also, it 
has been proposed that such interaction induces subtle per-
turbations in the higher order structure of a protein thus 
increasing fl exibility and lipophilicity by exposing buried 
hydrophobic residues, thus resulting in a more transport-
competent state (191,195,196). In vitro studies using intes-
tinal tissue have demonstrated that these agents facilitate 
drug absorption via trans-cellular diffusion without com-
promising the integrity of both the cell membrane or tight 
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In addition, such methods improve patient comfort by 
reducing the number of doctor visits, avoiding injections 
and facilitating administration. Membrane-based barriers 
such as the skin and mucosa have been extensively studied 
as potential drug delivery routes over the past decade. 
A mucosal barrier that has shown a great level of interest for 
both local and systemic delivery of peptides and proteins is 
the vaginal epithelium (212).
Vaginal non-invasive drug delivery, or the delivery of 
therapeutical molecules across the vaginal mucosa, both 
offer numerous advantages such as ease of access, prolonged 
retention, access to a highly rich vasculature, possibility of 
auto-administration, and a relatively low enzymatic activity. 
Intra-vaginal, non-invasive, drug delivery systems aim at 
enhancing permeability of the vaginal mucosa to the target 
peptide and/or protein moiety, and therefore provide an 
alternative administration route for peptide/protein-based 
therapies.
A genetically reconstructed fusion peptide of human 
epidermal growth factor (hEGF) with an undecapeptide 
YGRKKRRQRRR (P11), which have been shown to play 
important roles in ameliorating malfunctions in neurodegen-
erative diseases, was used by Zhao et al. (213) to investigate 
the permeability between cell membrane and the BBB via 
rectal administration. The results gathered by these research-
ers clearly suggest that the rectal non-invasive delivery of 
the P11 polypeptide-conjugated growth factor is an effi cient 
way for BBB transduction, thus raising the hope of real ther-
apeutical progress against neurodegenerative diseases via 
non-invasive rectal delivery.
CONCLUSIONS
Overcoming the need for (invasive) injection-based deliv-
ery of protein and/or peptide (bio)pharmaceuticals has been 
the driving force for intense research efforts exploring the 
feasibility of techniques allowing non-invasive administra-
tion of such macromolecules. Empowered with a much 
greater understanding of the intricate structural, physiologi-
cal and biochemical characteristics of each non-invasive 
route, researchers have begun to devise promising delivery 
technologies to overcome the signifi cant barriers posed to 
effective absorption of such biopharmaceutical macromol-
ecules into the systemic circulation. Most successful among 
the various non-invasive routes are several nasal delivery 
systems incorporating highly potent (commercially avail-
able) peptide moieties that have already gained regulatory 
approval. Advances in inhalation research have resulted in 
the development of at least three pulmonary delivery sys-
tems centered in insulin, one of which has received regula-
tory approval in both the USA and Europe. This fi rst 
successful approval may therefore open the way for addi-
tional pulmonary products to appear in the market, since the 
technology seems to be adaptable to other protein and pep-
tide (bio)pharmaceuticals. Despite signifi cant develop-
ments in the design of inhalation delivery systems for the 
nasal route, similar success has not yet been achieved for 
the buccal/sublingual, trans-dermal, vaginal, ocular, rectal 
or oral routes of administration. Some of the technologies 
under development have produced encouraging clinical 
updated overview of the advances made in ocular delivery 
of bioactive (hydrophilic) molecules, such as peptides 
and proteins, by means of chitosan-based nanosystems, and 
their potential relevance in clinical use. De la Fuente and 
co-authors (209) reported that their research group has 
designed and developed a delivery platform based on chito-
san nanoparticles, which suits the requirements for the topi-
cal ocular route. These nanosystems have been specifi cally 
adapted for the delivery of peptide/protein drugs onto the 
eye surface.
Therapeutical molecules for treating diseases at the pos-
terior segment of the eye are also emerging. Among them, 
protein drugs represent an important class of therapeutical 
entities (210). Topical administration of eye drops is the 
easiest way to deliver drugs. However, only less than 1/108 
of protein drug may reach the back of the eye. Systemic 
delivery is another way to deliver drugs to the posterior 
segment of the eye, but a large amount of drug is needed to 
attain the required therapeutic level since the blood-retinal 
barrier (BRB) restricts the infl ux of drugs to the retina 
(211). The trans-scleral route has attracted much interest as 
a potential path for delivering protein and/or peptide thera-
peutical moieties into the posterior segment of the eye. 
There are several advantages: fi rst, diffusion of macromol-
ecules through the sclera is feasible, as demonstrated in ex 
vivo diffusion experiments using rabbit sclera; and second, 
the distance for drug molecules to penetrate into the poste-
rior segment of the eye is shorter via the trans-scleral than 
via the trans-corneal route. After diffusing through the 
sclera, protein and/or peptide macromolecules are closer to 
the vicinity of the eye where most posterior diseases occur: 
the choroid and the retina. Cheung et al. (210) have 
explored the use of ultrasounds to non-invasively deliver 
protein therapeuticals into the sclera, so as to take advan-
tage of the trans-scleral route. However, there is currently 
no investigation regarding the effects of ultrasounds in 
delivering macromolecules through the sclera. In their 
studies, these authors performed ex vivo experiments using 
rabbit eyes and tracked albumin penetration using a fl uo-
rescence microscope following a short ultrasound expo-
sure. Cheung and colleagues (210) aimed at measuring the 
ultrasound enhancement of protein transport, proposed a 
potential mechanism for such transport and provided an 
initial assessment of the feasibility of such method.
Other Routes of Administration
As stated throughout the text, the commercial production of 
a variety of therapeutical molecules has intensifi ed the 
study of drug delivery systems to improve bioavailability, 
therapeutical effi cacy, and patient comfort. Effi cient drug 
delivery systems aim at delivering proteins and/or peptides 
to the systemic circulation or local tissues via non-invasive 
routes, while maintaining at the same time a suffi cient bio-
availability. Many non-invasive drug delivery methods 
involve overcoming membrane and enzymatic barriers, 
where the underlying principle consists in enhancing the 
permeability of the membrane to the target (bio)pharmaceu-
tical. The bioavailability is improved by both avoiding fi rst-
pass hepatic metabolism and achieving targeted delivery. 
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